BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 208 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 0.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $1,089,838 | +104.3% | 130,676 | +181.2% | 0.04% | +40.0% |
| Q4 2022 | $533,567 | -22.8% | 46,478 | -15.3% | 0.02% | +13.6% |
| Q3 2022 | $691,000 | +9.0% | 54,871 | -6.4% | 0.02% | +22.2% |
| Q2 2022 | $634,000 | -31.2% | 58,645 | +4.7% | 0.02% | 0.0% |
| Q1 2022 | $921,000 | +22.8% | 56,014 | +3.0% | 0.02% | +20.0% |
| Q4 2021 | $750,000 | -20.1% | 54,383 | -16.7% | 0.02% | -16.7% |
| Q3 2021 | $939,000 | +15.6% | 65,312 | +24.6% | 0.02% | +38.5% |
| Q2 2021 | $812,000 | +49.8% | 52,412 | -3.4% | 0.01% | +30.0% |
| Q1 2021 | $542,000 | -15.8% | 54,272 | -36.8% | 0.01% | -28.6% |
| Q4 2020 | $644,000 | +69.9% | 85,880 | -13.2% | 0.01% | +16.7% |
| Q3 2020 | $379,000 | +56.6% | 98,949 | +103.3% | 0.01% | +33.3% |
| Q2 2020 | $242,000 | – | 48,675 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management, LLC | 1,744,356 | $18,455,000 | 9.59% |
| RA Capital Management | 4,347,456 | $45,996,000 | 3.30% |
| Cormorant Asset Management, LP | 1,168,000 | $12,357,000 | 2.84% |
| Baker Brothers Advisors | 5,867,031 | $62,073,000 | 0.79% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 907,920 | $9,606,000 | 0.39% |
| QVT Financial LP | 525,734 | $5,562,000 | 0.32% |
| EAM Investors, LLC | 114,548 | $1,212,000 | 0.22% |
| FRANKLIN STREET ADVISORS INC /NC | 93,000 | $984,000 | 0.20% |
| THB ASSET MANAGEMENT | 301,529 | $3,190,000 | 0.19% |
| TPG Group Holdings (SBS) Advisors, Inc. | 1,162,269 | $12,297,000 | 0.13% |